Delving into the Latest Updates on Parecoxib Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide, Parecoxib sodium (USAN), Rayzon

+ [8]

Target

COX-2

Action

inhibitors

Mechanism

COX-2 inhibitors(Cyclooxygenase-2 inhibitors)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Pain, Postoperative

Inactive Indication

ColicRenal Colic

Originator Organization

Pfizer Inc.

Active Organization

Pfizer Australia Pty Ltd.Pfizer Europe MA EEIG

Pfizer Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

European Union (22 Mar 2002),

Pain, Postoperative

RegulationPriority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC19H18N2O4S

InChIKeyTZRHLKRLEZJVIJ-UHFFFAOYSA-N

CAS Registry198470-84-7

View All Structures (2)

The goal of this clinical trial is to learn if the administration of oxycodone for preventive analgesia works to reduce the chronification of acute postoperative pain in adult participants undergoing major abdominal surgery. The main question it aims to answer is:
• Does administration of oxycodone before surgical incision reduce the occurrence of chronic pain or relieve the chronic pain symptoms 3 months after the operation? Researchers will compare oxycodone + parecoxib sodium to placebo + parecoxib sodium combinations to see if oxycodone works to reduce the chronification of acute postoperative pain.
Participants will:
* Take oxycodone + parecoxib sodium or placebo + parecoxib sodium combinations before the surgical incision
* Cooperate with the follow-up staffs and complete some checkups or tests within 3 months after the operation.

Start Date01 Jan 2025

Sponsor / Collaborator

Tongji Hospital Tongji Medical College of HUST

[+2]

NCT06579274

/ Not yet recruitingPhase 2IIT

A Randomized, Placebo-controlled, Double-blind Clinical Trial Evaluating the Safety and Efficacy of Parecoxib in Hospitalized Patients With Spontaneous Subarachnoid Hemorrhage

Because of the important role of inflammation in the pathophysiology of SAH, it was hypothesized that its pharmacological manipulation might improve the prognosis of patients. In recent years, the effects of several groups of anti-inflammatory drugs on the development of complications after SAH have been described. Initially promising, glucocorticoids, thought to reduce cerebrovascular inflammation, brain swelling, and headache, failed in clinical trials. Studies have not provided clear evidence of the beneficial effects of these drugs in patients after SAH. Therefore, the administration of glucocorticoids is not currently part of the recommended practice. In addition, glucocorticoid treatment is associated with adverse effects that worsen outcomes, including hyperglycemia, infection, and the risk of gastrointestinal bleeding.

Start Date01 Jan 2025

Sponsor / Collaborator

St. Anne's University Hospital Brno

[+1]

100 Clinical Results associated with Parecoxib Sodium

Login to view more data

100 Translational Medicine associated with Parecoxib Sodium

Login to view more data

100 Patents (Medical) associated with Parecoxib Sodium

Login to view more data

1,300

Literatures (Medical) associated with Parecoxib Sodium

24 Jan 2025·Journal of Burn Care & Research

Effects of Parecoxib Sodium on Early Cognitive Impairment and Inflammation Levels in Burned Rats

Article

Author: Hu, Guangjun ; Zhang, Kun ; Chen, Zhuo ; Jiang, Xiaoyang ; Du, Siyu

AbstractTo study the effect of parecoxib sodium in alleviating inflammation in burned rats and restoring cognitive function in burned rats. A total of 30 specific pathogen free grade Sprague–Dawley rats were randomly divided into 6 groups: (1) blank control group (group C), (2) Sham surgery group (group Sham), (3) second-degree burn model (group B), (4) low-dose (1 mg/kg/d) parecoxib sodium (group L + B), (5) medium-dose (10 mg/kg/d) parecoxib sodium (group M + B), and (6) high-dose (20 mg/kg/d) parecoxib sodium (group H + B). ELISA measures inflammatory factors interleukin (IL)-2, IL-6, tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ), and cognitive function factors neuron-specific enolase (NSE), cortisol, and S-100β. Combined with water maze and dark-avoidance experiments to further verify the recovery of cognitive function in rats. The contents of IL-2, TNF-α, and IL-6 in group M + B were significantly lower than those in group Sham (P < .05), and the content of IFN-γ was significantly lower than that in group Sham (P < .05). The cognitive markers NSE, S-100β, and cortisol levels in group M + B were significantly higher than those in group Sham at 2 h, 1 d, 5 d, and 10 d after operation (P < .05). In the group M + B dark-avoidance experiment, the number of probes and errors was not significantly different than those in group Sham and group C (P > .05), and the number of times group M + B found a platform in the water maze experiment and crossed the platform was second only to group B and group C. Parecoxib sodium can effectively reduce inflammation in burn rats and promote cognitive recovery in burn rats, and the optimal dose of parecoxib sodium for burn rats is 10 mg/kg.

31 Dec 2024·International Journal of Hyperthermia

Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy

Article

Author: Chang, Sheng-Chi ; Yeh, Hung-Chieh ; Ho, Chien-Lin ; Cheng, Chih-Chung ; Su, Pei-Wen

PURPOSECisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney disease (CKD) is scarce and less investigated. This study aims to investigate the incidence of CKD following cisplatin-based HIPEC and to analyse the associated risk factors.MATERIALS AND METHODSFrom January 2016 to August 2021, a total of 55 patients treated with CRS and cisplatin-based HIPEC for peritoneal carcinomatosis were categorized retrospectively into groups, with and without CKD. Demographics, comorbidity, surgery, postoperative management, and complications were collected to evaluate risk factors for cisplatin-based HIPEC-related CKD. Univariate and multivariate analyses were conducted to confirm the correlation between different variables and CKD occurrence.RESULTSOf the 55 patients, 24 (43.6%) patients developed AKI and 17 (70.8%) patients of these AKI patients progressed to CKD. Multivariate regression analysis identified intraoperative use of parecoxib (Odds Ratio (OR) = 4.39) and intraoperative maximum temperature > 38.5°C (OR = 6.40) as major risk factors for cisplatin-based HIPEC-related CKD occurrence. Though type II diabetes mellitus and intraoperative complications were the independent risk factors of AKI following cisplatin-based HIPEC, but they were not shown in CKD analysis.CONCLUSIONIntraoperative use of parecoxib during cisplatin-based HIPEC emerged as a significant risk factor for postoperative CKD. Clinicians should exercise caution in prescribing parecoxib during HIPEC procedures. Additionally, maintaining intraoperative body temperature below 38.5°C might be crucial to mitigate the risk of CKD development. This study underscores the importance of identifying and preventing specific risk factors to improve long-term renal outcomes in patients undergoing cisplatin-based HIPEC.

01 Dec 2024·Neuropharmacology

Increased levels of Escherichia-Shigella and Klebsiella in the gut contribute to the responsivity of placebo analgesia

Article

Author: Hu, Suwan ; Yang, Chun ; Liu, Cunming ; Wang, Di ; Yang, Siqi ; Wu, Zifeng ; Bu, Yuchen ; Zhang, Qi ; Zhang, Xinying ; Huang, Chaoli ; Wang, Yuanyuan

Placebo analgesia is observed in both humans and animals. Given the complexity of placebo analgesia involving a variety of neurobiological, psychological, and psychosocial processes, further investigation into its underlying mechanisms is essential. Gut microbiota has been implicated in the responsivity of placebo analgesia, but its precise role remains unknown and warrants further investigations. Here, we conducted a conditioning training model with chronic inflammatory pain induced by complete Freund's adjuvant (CFA) in mice, associating parecoxib with different cues. Hierarchical clustering analysis of placebo analgesia behaviors was employed to classify mice into responders and non-responders phenotypes. Approximately 40% of CFA mice undergoing conditioning training exhibited placebo analgesia. Notably, placebo analgesia responders displayed reduced anxiety-like behaviors. 16S rRNA results revealed a distinct composition of gut microbiota composition among the control, placebo analgesia non-responders and responders groups. Notably, levels of Escherichia Shigella and Klebsiella in the gut were increased considerably in the placebo analgesia responders as compared to both control and non-responders groups. In conclusion, placebo analgesia responders demonstrated marked analgesia, reduced anxiety-like behaviors, and increased levels of Escherichia-Shigella and Klebsiella, implying a potential linkage between gut microbiota and placebo analgesia.

100 Deals associated with Parecoxib Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03717	Parecoxib Sodium	M01AH04	DB08439

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pain, Postoperative	Norway	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	Iceland	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	European Union	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	Liechtenstein	Pfizer Europe MA EEIG	22 Mar 2002

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain	Preclinical	Australia	Pfizer Inc.	01 Apr 2003
Colic	Preclinical	Italy	Pfizer Inc.	01 Apr 2002
Renal Colic	Preclinical	Italy	Pfizer Inc.	01 Apr 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ILCA2020	Phase 3	Hepatocellular Carcinoma	80	Parecoxib sodium 40 mg	qtovbsnkyz(qwzkhskdsy) = lipuxyhsxw nbarqbzaxd (fqxnqomtaw, 9.8 - 28.2) View more	Positive	13 Sep 2020
				Placebo	qtovbsnkyz(qwzkhskdsy) = ypjsrvgdrn nbarqbzaxd (fqxnqomtaw, 8.1 - 19.9) View more
ILCA2020	Not Applicable	Hepatocellular Carcinoma	-	Parecoxib sodium + TAP block	gzisfqqmlo(pgypfmaelk) = No significant differences were found between the two groups related to adverse events mgiwlhehnl (zcdebdwywb ) View more	Positive	13 Sep 2020
NCT03059238 (ASCO_GI2020)	Phase 3	Hepatocellular Carcinoma	213	Celecoxib	(mtrywzwmpn) = njtbibkikj czquqpifgh (oajoprvnca )	Positive	04 Feb 2020
				Parecoxib	(mtrywzwmpn) = oqmzfcyuol czquqpifgh (oajoprvnca )
NCT01566669 (PCEA, Pubmed \| PLoS One)	Not Applicable	-	240	Parecoxib	jbxotxksbj(wnwqvuramh) = xrzisvknok bxthvvgovy (ndjncgczvx ) View more	Positive	01 Jan 2016
				Placebo	jbxotxksbj(wnwqvuramh) = zghhapxyrt bxthvvgovy (ndjncgczvx ) View more
NCT00346268 (PROSTATECTOMY, Pubmed \| BMC Anesthesiol) Manual	Phase 4	Hemorrhage \| Analgesia	105	Morphine+parecoxib	iemztkrkjm(djdjypdylm) = typufyyajg wtpsvaqolz (usuxwcfjmv, 24.1) View more	Positive	09 Mar 2015
				Morphine+Placebo	iemztkrkjm(djdjypdylm) = gairpkqjrr wtpsvaqolz (usuxwcfjmv, 28) View more
NCT00553605 (NAP, CTgov)	Phase 4	Renal Colic	340	Parecoxib (Parecoxib)	ngtrbrskcy(gwrkzlcqwy) = lhqkxlhxpc rdtsyarubj (scewdxyrrc, yevxkamgfo - qbzdckrfug) View more	-	28 Jan 2013
				Ketoprofen (Ketoprofen)	ngtrbrskcy(gwrkzlcqwy) = fdpprqfuxr rdtsyarubj (scewdxyrrc, mtodlrnpwt - mbvpodrghm) View more
NCT00346268 (PROSTATECTOMY, CTgov)	Phase 4	Pain, Postoperative	105	Parecoxib+Morphine (Parecoxib and Morphine)	kzloeshlaq(nctajchvbt) = mgjxhbcuzz qmwmvoyndw (kgsnhatuuf, plwwrshgeh - oqgmdketmn) View more	-	28 Oct 2011
				Placebo+Morphine (Placebo and Morphine)	kzloeshlaq(nctajchvbt) = xeakpmllah qmwmvoyndw (kgsnhatuuf, ehmhvqeapd - cybguqirth) View more
NCT00455117 (Pubmed \| Br J Anaesth)	Phase 4	Pain, Postoperative	-	Parecoxib 40 mg	psuzatofov(ahtdpqujww) = khtdlqauem ejlysifyqc (omnrzurgfl )	Negative	01 Sep 2011
				Placebo	psuzatofov(ahtdpqujww) = jdqkvlplbe ejlysifyqc (omnrzurgfl )